KIT and gastrointestinal stromal tumor: One of the molecular targeted drugs that was approved for solid tumors in the early days is imatinib, a tyrosine kinase inhibitor (TKI) targeting c-kit (CD117), which is specifically expressed in gastrointestinal stromal tumors (GISTs) [40].